Pfizer Inc. and Blueprint Medicines Corporation: SG&A Spending Patterns Compared

Pfizer vs. Blueprint: SG&A Spending Trends Unveiled

__timestampBlueprint Medicines CorporationPfizer Inc.
Wednesday, January 1, 2014789000014097000000
Thursday, January 1, 20151445600014809000000
Friday, January 1, 20161921800014837000000
Sunday, January 1, 20172798600014784000000
Monday, January 1, 20184792800014455000000
Tuesday, January 1, 20199638800014350000000
Wednesday, January 1, 202015774300011615000000
Friday, January 1, 202119529300012703000000
Saturday, January 1, 202223737400013677000000
Sunday, January 1, 202329514100014771000000
Monday, January 1, 202435927200014730000000
Loading chart...

Unlocking the unknown

A Tale of Two Companies: SG&A Spending Trends

In the ever-evolving pharmaceutical industry, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, Pfizer Inc. and Blueprint Medicines Corporation have demonstrated contrasting approaches to their Selling, General, and Administrative (SG&A) expenses.

From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually, with a slight dip in 2020. This consistency reflects Pfizer's established market presence and operational efficiency. In contrast, Blueprint Medicines has shown a dramatic increase in SG&A spending, growing from a modest $7.9 million in 2014 to nearly $295 million in 2023. This 37-fold increase underscores Blueprint's aggressive expansion and investment in market penetration.

These spending patterns highlight the different growth stages and strategic focuses of these two companies, offering a fascinating glimpse into their corporate trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025